Search

Displaying results 2421 - 2430 of 10000 in total
  1. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  2. Drug

    KB002

    go.drugbank.com/drugs/DB05194
    Experimental

    KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.

  3. Drug

    Zafirlukast

    go.drugbank.com/drugs/DB00549
    Approved

    Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. … It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.

    Synonyms: 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide
  4. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) [A31983]. … Structurally, it is classified as a tricyclic antidepressant (TCA), however, it possesses different pharmacological properties than typical tricyclic antidepressants [A31969].

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  5. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    Garadacimab is a fully human monoclonal antibody targeted against activated factor XII. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.

  6. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

  7. Drug

    Ergotamine

    go.drugbank.com/drugs/DB00696
    Approved

    A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  8. Drug

    Fluoxymesterone

    go.drugbank.com/drugs/DB01185
    ApprovedIllicit

    An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.

  9. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    another ROS1 inhibitor has failed rather than as an alternative first choice. … Zidesamtinib is an orally administered ROS1 kinase inhibitor designed to remain active against ROS1 resistance mutations.

  10. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK